Romanian oil and gas group OMV Petrom reported a 57% slump in its fourth-quarter adjusted operating profit on Tuesday, citing ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

In obesity, Lilly removed a dual amylin calcitonin receptor agonist (DACRA) from its phase 1 pipeline. Lilly got into DACRAs ...

Eli Lilly (LLY) stock rises as company posts Q4 2024 results, beating expectations with a twofold rise in revenue from weight ...

Eli Lilly & Co.’s full-year earnings forecast came in line with analysts’ estimates as the company works to fix inventory ...

Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, banking on the launch of its popular ...

Eli Lilly's Q4 revenue surged 45% to $13.53 billion, fueled by Mounjaro and Zepbound. 2025 guidance forecasts up to $61 billion in sales, driven by new drug launches.

Erste Group upgraded Eli Lilly (LLY) to Buy from Hold. Eli Lilly has products that are in high demand as well as “an extensive pipeline of ...

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $732 billion, has been ...

Eli Lilly is set to report fourth-quarter earnings early Thursday, with analysts expecting rising sales and profit in the first full quarter with the company's weight-loss drugs no longer in shortage.

Eli Lilly Chief Corporate Brand Officer Lina Polimeni on how the brand differentiates itself in the crowded pharma market, ...

Over the past six months, Eli Lilly (NYSE: LLY) has underperformed broader equities. While that's not much of an issue in the grand scheme of things, it is still a bit surprising, since the ...